Egis has launched to the Russian market a new ezetimibe of European quality that helps to achieve the target level of low-density lipoprotein cholesterol in cases where the statin therapy is not enough. The drug is produced in Hungary (EU) in accordance with Good Manufacturing Practices (GMP). At the same time, the new product is more affordable compared to the original ezetimibe [6], which ensures its high attractiveness for Russian doctors and their patients. The product has already been registered in Russia and sold in Russian pharmacies from October 2021.

Two technology-intensive developments, carried out with state subsidies, were completed at Egis Pharmaceuticals PLC’s Körmend site (Hungary). The investments were inaugurated by Péter Szijjártó, Minister of Foreign Affairs and Trade, and by the company’s CEO, Dr. István Hodász on 15 October.  In addition to a new packaging plant, Egis has also established a plant with special knowledge and technology requirements, typically suitable to manufacture oncology products.  Thus, Egis is now able to implement all value-creating processes within the field of oncology, from development to active ingredient and finished product manufacturing.

Hungarian-based Egis Pharmaceuticals PLC launch in Russia the first fixed drug combination of two lipid-lowering agents: rosuvastatin and ezetimibe.